Tevogen Bio (NASDAQ:TVGN) Receives Buy Rating from D. Boral Capital

Tevogen Bio (NASDAQ:TVGN - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 target price on the stock.

Tevogen Bio Trading Up 2.3%

Tevogen Bio stock traded up $0.03 during mid-day trading on Tuesday, reaching $1.34. 416,553 shares of the company traded hands, compared to its average volume of 5,024,943. Tevogen Bio has a fifty-two week low of $0.26 and a fifty-two week high of $3.09. The firm's fifty day moving average is $1.09 and its two-hundred day moving average is $1.22.

Insiders Place Their Bets

In related news, insider Neal Flomenberg sold 70,384 shares of Tevogen Bio stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $1.09, for a total transaction of $76,718.56. Following the completion of the transaction, the insider now directly owns 3,898,828 shares in the company, valued at approximately $4,249,722.52. This trade represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have sold 406,510 shares of company stock valued at $446,763. Company insiders own 73.24% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TVGN. Nuveen LLC acquired a new stake in Tevogen Bio during the first quarter valued at $97,000. Northern Trust Corp boosted its stake in shares of Tevogen Bio by 13.0% during the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company's stock worth $122,000 after acquiring an additional 13,595 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Tevogen Bio during the 4th quarter worth about $55,000. Barclays PLC grew its position in shares of Tevogen Bio by 39.2% during the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock valued at $48,000 after acquiring an additional 12,847 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Tevogen Bio by 31.2% during the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock valued at $465,000 after acquiring an additional 107,566 shares during the period.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.